Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement


ABSTRACT

Purpose
The primary purposes of eligibility criteria are to protect the safety of trial participants and define the trial population. Excessive or overly restrictive eligibility criteria can slow trial accrual, jeopardize the generalizability of results, and limit understanding of the intervention’s benefit-risk profile.

Methods
ASCO, Friends of Cancer Research, and the US Food and Drug Administration examined specific eligibility criteria (ie, brain metastases, minimum age, HIV infection, and organ dysfunction and prior and concurrent malignancies) to determine whether to modify definitions to extend trials to a broader population. Working groups developed consensus recommendations based on review of evidence, consideration of the patient population, and consultation with the research community.

Results
Patients with treated or clinically stable brain metastases should be routinely included in trials and only excluded if there is compelling rationale. In initial dose-finding trials, pediatric-specific cohorts should be included based on strong scientific rationale for benefit. Later phase trials in diseases that span adult and pediatric populations should include patients older than age 12 years. HIV-infected patients who are healthy and have low risk of AIDS-related outcomes should be included absent specific rationale for exclusion. Renal function criteria should enable liberal creatinine clearance, unless the investigational agent involves renal excretion. Patients with prior or concurrent malignancies should be included, especially when the risk of the malignancy interfering with either safety or efficacy endpoints is very low.

Conclusion
To maximize generalizability of results, trial enrollment criteria should strive for inclusiveness. Rationale for excluding patients should be clearly articulated and reflect expected toxicities associated with the therapy under investigation.

J Clin Oncol 35. © 2017 by American Society of Clinical Oncology

INTRODUCTION

Eligibility criteria are a foundational component of clinical trials and serve to define the patient population under study. They can be inclusionary, by, for example, specifying a tumor type or molecular alteration needed for study entry, or exclusionary, by specifying certain characteristics, such as laboratory test values, history of prior and concurrent malignancies, minimum age, or comorbidities, that would render a patient ineligible for enrollment. The primary purposes of eligibility criteria are to protect the safety of patients who participate in clinical trials and to define the characteristics of the study population. Excessive or overly restrictive eligibility criteria can impair clinical trial accrual and completion and prevent patients from accessing investigational interventions that may provide clinical benefit. Narrowly defined trial populations may also jeopardize the generalizability of trial results and limit the ability to understand the therapy's benefit-risk profile across the broad patient population who ultimately may receive the intervention in the postmarket setting.
Modernizing eligibility criteria was a key objective of the November 2011 ASCO Blueprint for Transforming Clinical and Translational Cancer Research. ASCO believed that an increasing number and complexity of eligibility criteria were compromising recruitment to clinical trials. A working group of the ASCO Cancer Research Committee conducted an analysis of clinical trials and survey of investigators and developed a recommended strategy to formulate inclusion and exclusion criteria, as well as encourage continuous reassessment of criteria throughout the research process. The resulting article provided a list of key questions to help focus trial designers on the relationship of criteria to the study objectives, generalizability of results, and risks to patients.

ASCO, in collaboration with Friends of Cancer Research (Friends), launched a collaborative initiative to reassess the approach for determining clinical trial eligibility. ASCO, Friends, and the US Food and Drug Administration (FDA) used the recommendations from ASCO’s original work to identify specific eligibility criteria that were most likely to restrict patients’ participation in trials and were least likely to impact the safety of trial participants. The project leadership initially selected the following four topics that commonly lead to exclusion of patients from clinical trials: brain metastases, minimum age for enrollment, HIV infection, and organ dysfunction and prior and concurrent malignancies. Each of these topics was explored by working groups composed of multiple stakeholders, including investigators, patient advocates, biostatisticians, pharmacologists, manufacturers, and regulators. The working groups reviewed the state of the science and existing studies in the literature and attempted to balance the needs of protecting patient safety, facilitating access to investigational therapies, and protecting trial integrity (including safety, efficacy, statistical, and operational considerations). The working groups engaged in multiple meetings to discuss their concerns and reached consensus on approaches that could be implemented to broaden eligibility criteria and enable recruitment of a trial population that is more representative of the population of patients with the given cancer who are the intended users of the intervention being studied. The draft recommendations were presented and vetted among all the working groups at a May 2016 workshop and were discussed at a public meeting in November 2016—the Friends Annual Meeting on Clinical Cancer Research. Representatives from the National Clinical Trials Network (NCTN) provided examples at the November meeting of ongoing efforts within the NCTN groups to appropriately expand eligibility criteria.

Detailed discussion of each of the working group recommendations is included in separate manuscripts that have been submitted for publication. This statement provides a high-level summary of each of the working group recommendations and discusses overarching principles to guide implementation. Recommended language for use in clinical trial protocols is included in Table 1.

**Brain Metastases**

Broad or conditional exclusion of patients with brain metastases is common despite the high incidence of brain metastases in some tumor types. An FDA analysis of 250 Investigational New Drug applications for 2015 found that less than half permitted enrollment of patients with previously treated, inactive, and/or stable brain metastases (Jin et al, manuscript submitted for publication). Although life expectancy may be reduced for some patients with brain metastases and there have been concerns regarding a potentially greater risk of neurologic toxicity, existing literature does not indicate that these patients experience higher rates of serious adverse events. This working group developed recommendations specific to patients with treated or stable brain metastases; patients with new, active, or progressive brain metastases; and patients with leptomeningeal disease.

- Patients with treated and/or stable brain metastases (eg, no progression for at least 4 weeks after local prior therapy;
<table>
<thead>
<tr>
<th>Patient Subgroup</th>
<th>Text Template</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients with treated/stable brain metastases</td>
<td>Template for inclusion: Patients with treated brain metastases are eligible if there is no evidence of progression for at least 4 weeks after CNS-directed treatment, as ascertained by clinical examination and brain imaging (MRI or CT) during the screening period.</td>
</tr>
<tr>
<td>Patients with new, active, or progressive brain metastases</td>
<td>Guidance for inclusion in early-phase trials: Patients with active brain metastases should be included early in clinical development when there is strong scientific rationale for likelihood of benefit, based on molecular pathways or histology and preclinical data. For drugs/modalities with less robust preclinical information on potential CNS activity, inclusion of patients with active brain metastases should still be considered, particularly if brain metastases are common in the intended use population. The inclusion of a CNS-specific cohort can provide valuable dosing and preliminary efficacy data to either support or refute inclusion in later phase trials. Guidance for inclusion in later phase trials: Ideally, data from earlier phase trials, in concert with the strength of the scientific rationale and preclinical data, can inform decisions on inclusion of patients with active brain metastases in later phase trials. When such data are not available, several potential trial designs could allow patients with active brain metastases to enroll, either as a parallel cohort or as a defined subset within the larger clinical trial.</td>
</tr>
<tr>
<td>Patients with LMD</td>
<td>Guidance for inclusion: See above considerations.</td>
</tr>
<tr>
<td>• If patients with LMD are to be excluded, the following wording is suggested to avoid unnecessary exclusion of patients with imaging-only equivocal findings. Guidance for exclusion: For the purposes of exclusion, LMD is a clinical diagnosis, defined as positive CSF cytology and/or unequivocal radiologic or clinical evidence of leptomeningeal involvement. Patients with leptomeningeal symptoms in the setting of leptomeningeal enhancement by imaging (MRI) would be considered to have LMD even in the absence of positive CSF cytology, unless a parenchymal lesion can adequately explain the neurologic symptoms and/or signs. In contrast, an asymptomatic or minimally symptomatic patient with mild or nonspecific leptomeningeal enhancement (MRI) would not be considered to have LMD. In that patient, CSF sampling is not required to formally exclude LMD, but can be performed at the investigator’s discretion based on level of clinical suspicion. Template for exclusion: No known LMD.</td>
<td></td>
</tr>
<tr>
<td>Patients younger than age 18 years</td>
<td>Guidance for inclusion in early-phase trials: Pediatric-specific cohorts should be included when there is strong scientific rationale for likelihood of benefit, based on molecular pathways or histology as well as preclinical data. Templates for inclusion • Adolescent/pediatric patients age [protocol author to insert age minimum and maximum specific to the study under consideration] will be included after enrollment of adult patients after safety and toxicity in the adult population have been established. Participating sites will be notified when adolescent/pediatric patient enrollment may begin. • Adolescent/pediatric patients age [protocol author to insert age minimum and maximum specific to the study under consideration] will be included starting one dose cohort behind the current adult cohort in which there are no dose-limiting toxicities identified. Participating sites will be notified when enrollment onto the adolescent/pediatric stratum may begin. • Adolescent/pediatric patients age [protocol author to insert age minimum and maximum specific to the study under consideration] will be included in age-specific cohorts that will be staggered starting one dose cohort behind the current adult cohort in which there are no dose-limiting toxicities identified. Participating sites will be notified when each adolescent/pediatric cohort enrollment may begin. • Adolescent/pediatric patients age [protocol author to insert age minimum and maximum specific to the study under consideration] are included in this trial in a separate cohort that will accrue simultaneous to the adult cohort [specify age 18 and older or protocol-specific upper age limit] and be included starting one dose cohort behind the current adult cohort in which there are no dose-limiting toxicities identified. Participating sites will be notified when each adolescent/pediatric cohort enrollment may begin.</td>
</tr>
</tbody>
</table>
should be routinely included in prospective clinical trials of all phases and only excluded if there is compelling rationale for exclusion. If there are specific safety concerns, then tailoring specific criteria to the concern is preferable to general exclusion of all patients with brain metastases.

- For patients with active (eg, untreated or progressive) brain metastases, the working group recommends that such patients not be automatically excluded. However, a one-size-fits-all approach is not appropriate, and factors such as natural history of the disease, trial phase and design, and the drug’s mechanism of action, pharmaceutical properties, and potential for CNS penetration should determine whether such patients are included in a trial. If patients with active brain metastases are included, additional prospective planning may be required to better define safety and treatment response. Early stopping rules may be appropriate should excessive toxicity and/or lack of efficacy be observed.

- In most trials, it remains appropriate to exclude patients with leptomeningeal disease as a result of their poor prognosis, although there may be situations that warrant a cohort of such patients in early-phase trials (eg, when CNS activity is anticipated), and these data could then support inclusion of such patients in later phase trials. If patients with leptomeningeal disease are excluded, justification for such exclusion should be provided alongside the exclusion criteria.

**Minimum Age for Enrollment**

Children and adolescents under the age of 18 years have traditionally been excluded from participating in clinical trials with novel agents until extensive data are available from studies of adults, often years after the introduction and approval of an agent. Because pediatric patients have historically been considered a vulnerable population, there is concern that a high proportion of pediatric patients have a low risk of AIDS-related outcomes should be included in cancer clinical trials unless there is a specific rationale to exclude such patients.

- Eligibility criteria should be straightforward and focus on current and past CD4+ T-cell counts, history (if any) of AIDS-defining conditions (eg, opportunistic infections), and status of HIV treatment. Healthy HIV-positive participants should be included when There is strong scientific rationale for likelihood of benefit, based on molecular pathways or histology or preclinical data. These cohorts would assess dose and pharmacokinetics separately in the pediatric population. Staggered enrollment starting with older children followed by younger children could be considered to address potential concerns specific to older pediatric patients, including not only metabolic differences but also challenges related to the availability of appropriate formulations for young children.

**HIV Infection**

Many people infected with HIV now have a normal life expectancy as a result of substantial improvements in HIV treatment over the past 20 years. Cancer is now a leading cause of mortality in people with HIV; however, most oncology studies exclude this population, as confirmed by the FDA analysis of 2015 Investigational New Drug applications. Only five (1.7%) of 250 protocols allowed enrollment of HIV-positive patients with stable disease and/or adequate CD4+ T-cell counts (Jin et al, manuscript submitted for publication). A review of HIV eligibility criteria in recent industry-supported studies leading to successful new drug applications conducted by the working group found that zero of 46 studies contained inclusion criteria for patients with HIV, 30 studies contained exclusion criteria, and nine studies discussed general exclusion of patients with active infection but did not specify HIV infection. The HIV Working Group recommended the following eligibility considerations in cancer studies.

- Patients with cancer who are healthy and have a low risk of AIDS-related outcomes should be included in cancer clinical trials unless there is a specific rationale to exclude such patients.

---

**Table 1. Recommended Protocol Text (continued)**

<table>
<thead>
<tr>
<th>Patient Subgroup</th>
<th>Text Template</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cardiac function</td>
<td>Guidance for cardiac function criteria: Measurement should include investigator assessment of a potential participant’s risk for heart failure with a validated clinical classification system (eg, the New York Heart Association Functional Classification).</td>
</tr>
<tr>
<td>Prior and concurrent malignancies</td>
<td>Guidance for inclusion: Inclusion of patients with prior or concurrent malignancies is recommended, especially when the risk of the malignancy interfering with either safety or efficacy endpoints is very low. Template for inclusion: Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen should be included.</td>
</tr>
</tbody>
</table>

Abbreviations: ADME, absorption, distribution, metabolism, and excretion; CT, computed tomography; LMD, leptomeningeal disease; MRI, magnetic resonance imaging.
who are included in cancer clinical trials should be treated using the same standards as trial participants with other comorbidities. Antiretroviral therapy should be considered a concomitant medication.

- Eligibility criteria for cancer clinical trials should allow for the patient to be treated concurrently with standard antiretroviral therapy (ART) following Department of Health and Human Services treatment guidelines.20 In cases where ART therapy may interact with cancer therapy, specific ART agents may be excluded.

Organ Dysfunction and Prior and Concurrent Malignancies

This working group first evaluated the types of organ dysfunction that were likely to drive most clinical trial exclusion criteria. The areas of focus included kidney, heart, and liver dysfunction, as well as exclusion based on a history of a previous malignancy. The group conducted analysis of these criteria from a large, representative data set that included a cohort of nearly 13,000 newly diagnosed patients with breast, colon, lung, and bladder cancers from 2013 to 2014. The analysis, as well as review of the literature, helped determine which of the organ dysfunction criteria to prioritize for development of recommendations.21

- Renal function criteria should be based on creatinine clearance rather than serum creatinine levels. In situations where renal excretion is not a significant component of a drug’s clearance, liberal creatinine clearance criteria (eg, >30 mL/min) should be used. Both the Cockcroft-Gault equation and the estimated glomerular filtration rate from the Modification of Diet in Renal Disease Study are reliable methods to estimate creatinine clearance.22 Trial sponsors should choose one of these methods and use it consistently across the research process. Established dose-modification strategies can allow safe and effective administration. Conservative criteria remain appropriate for nephrotic drugs.

- Currently clinically available tests of hepatic function (eg, tests of serum aminotransferases [ALT and AST] and bilirubin) inadequately describe liver function, particularly drug metabolism capability. In the absence of alternate testing methods, trials should continue to use standard clinical assessments of liver function relative to institutional normal ranges and avoid imposing a universal cutoff point that may be unnecessarily restrictive.

- If an investigational therapy is not known to pose cardiac risks, arbitrary ejection fraction values should not be used to exclude patients from clinical trials. Trials should recommend investigator assessment of a potential participant’s risk for heart failure with a validated clinical classification system, such as the New York Heart Association Functional Classification.23 Concern about cardiac effects often leads to frequent ECG monitoring in early-phase trials to determine eligibility and ongoing risk for QT/QTc prolongation.24 Continued ECG monitoring should be eliminated in later phases if cardiac risk is not determined to be a concern.

- Exclusions based on a history of prior malignancy or presence of concurrent malignancy should be liberalized, both in terms of when the malignancy occurred and was treated and types of prior malignancies. Inclusion of patients with prior or concurrent malignancies is recommended, especially when the risk of the malignancy interfering with either safety or efficacy endpoints is very low. Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen should be included.

Through the course of the working group discussions, potential benefits and risks of expanding eligibility criteria were identified (Table 2). As previously stated, the primary purpose of eligibility criteria is to protect the safety of clinical trial participants who may have characteristics that place them at increased risk for an adverse event from the intervention being studied. Thus, arguments against the use of broader eligibility criteria center on the concern that the development of an effective drug could be jeopardized if a serious adverse event occurs in a patient population that is inherently sicker or vulnerable. Inclusion of some patients may require additional screening or monitoring or the engagement of additional expertise to manage safety issues specific to that patient population. This would help to mitigate risk in these patients but could also increase trial cost and complexity.

In some cases, the working groups concluded that eligibility criteria should be broadened for all trial participants, particularly when a drug’s known or expected safety profile does not pose inordinate risks to participants. In other cases, sponsors could consider enrolling an expanded, more heterogeneous population and exclude these patients from the primary efficacy analysis, so as not to compromise assessment of the drug’s efficacy, but include them in the safety analysis. Strategies could include enrolling restricted and expanded populations in the same clinical trial (Jin et al, manuscript submitted for publication), conducting simultaneous clinical trials and analyzing separately, or using an extended trial design to expand knowledge in particular populations, such as the elderly, by enriching the primary study population with such individuals.25 Additional potential study design options that can be considered to address these concerns and potentially mitigate risk are listed in Table 3.

Although incorporation of an expanded trial population could present additional operational considerations, this practice could be accompanied by incentives such as the potential for expanded label indications resulting in competitive marketing claims. In addition, there is the potential for inclusion of additional information in the label’s prescribing information to help guide clinicians in adjusting administration and dosing in different populations. Adequate data generated in the clinical trial on under-represented populations, such as those with organ impairment, may obviate requirements for postmarketing studies. Discussion with regulators is encouraged to determine the best approach for each situation.

Cooperative groups have adapted eligibility criteria over the years. A review of Eastern Cooperative Oncology Group lung cancer trials determined that patients with prior malignancies were excluded from 94% of trials that used survival as a primary end point and 73% of trials that used other primary end points.26 Prior

DISCUSSION

jco.org

Downloaded from ascopubs.org by NIH LIBRARY on October 20, 2017 from 156.040.216.004
Copyright © 2017 American Society of Clinical Oncology. All rights reserved.
malignancies did not impact survival outcomes in patients with stage IV lung cancer or locally advanced lung cancer, suggesting that clinical trial outcomes would not be adversely impacted by inclusion of patients with a history of prior cancer. This analysis led the Alliance in Clinical Trials in Oncology Group to develop more inclusive criteria for patients with advanced lung cancer. The National Cancer Institute NCTN is also broadening eligibility criteria and changing clinical trial designs to address slow patient accrual. The Southwest Oncology Group revised the eligibility criteria of phase III trials of advanced NSCLC in a stepwise manner. From 1995 to 2014, the Southwest Oncology Group launched three NSCLC trials (S9509, S1400, and S1403) and progressively expanded its approach to inclusion of patients with brain metastases and prior malignancies.

ASCO’s Targeted Agent and Profiling Utilization Registry (TAPUR) Study has broad inclusion criteria of patients with prior and concurrent malignancies not requiring treatment, brain metastases, and HIV infection, and is in the process of lowering eligibility age from 18 to 12 years for drugs that have an established pediatric dose or drugs in which the pediatric dose can be derived from data from adult clinical trials. The TAPUR protocol enables patients with any prior or concurrent cancer to participate. Patients with brain metastases can participate, as long as the treatment of the brain metastases has been completed, the metastases are not progressive, and the patient has been off corticosteroids for at least 1 month. Patients also cannot have experienced a seizure or had a clinically significant change in neurologic status within 3 months of enrollment. Patients with HIV infection are allowed to enroll at the clinical investigator’s discretion, except for two study drugs with exclusions based on active HIV infection.

Fundamentally changing the approach to eligibility criteria requires a culture change across the entire clinical trials enterprise. At the design phase, investigators and trial sponsors should approach study development with an inclusive mindset, taking into consideration the safety profile of the investigational therapy, standard-of-care treatment, and the characteristics of the indicated population. A standard of inclusion, unless otherwise specified, would give investigators the responsibility to provide rationale and use their own clinical judgment and discretion as to why patients should be excluded from trial participation. Known or suspected risks of the investigational therapy should be the primary factors that warrant exclusion of patients. These risks should be outlined in a concise, easy-to-read format and provided to investigators, pharmacists, and the clinical research team for review. As

| Table 2. Benefits and Risks of Expanded Eligibility Criteria |
|----------------------------------|----------------------------------|
| Benefit and Risk | Patients and Physicians | Sponsors and Investigators |
| Benefits | Earlier access to investigational agents and expanded trial and treatment options | Ability to generalize to real-world patients and potentially reduce postmarketing requirements |
| | More complete safety data, which can inform clinical use and enable safe delivery if investigational agent becomes commercially available | Faster accrual; more patients may be eligible at each site, which may reduce the overall number of sites needed to successfully complete accrual |
| | Availability of efficacy and safety data can inform weighing of commercially available treatment options across a broader array of patients and increase confidence in therapy selection | Identification of potential safety issues during clinical trials may facilitate early development of mitigation strategies, enabling broader uptake after approval |
| | Earlier identification of drugs that may not be efficacious in a particular patient population or that may cause more harm than good | Efficacy in traditionally understudied population could potentially result in expanded marketing claims and provide a differentiating factor between drugs of same class |
| Risks | Limited data from small cohorts may not be adequate for clinical decision making | More variability in outcomes: may require larger sample sizes and inferences may not be as precise |
| | Patients who are inherently sicker may have higher risk of experiencing an adverse event as a result of the drug or disease | Potential safety concerns: may require separate cohorts or analysis plans and early stopping rules for excess toxicity |
| | Additional procedures for increased safety monitoring in some situations may incur additional costs to patients and/or the study | May complicate attribution of adverse events: consider randomization and data from other drugs in class |
| | Additional resources may be required to ensure clinical and research staff are capable of managing the additional patients on study | Increased costs associated with additional cohorts, statistical requirements, additional testing, or special expertise to manage specific patient needs |

<table>
<thead>
<tr>
<th>Table 3. Potential Trial Designs and Considerations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trial Designs and Considerations</td>
</tr>
<tr>
<td>Early-phase trials</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Later phase trials</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>
information is gathered over the duration of a trial, eligibility criteria should be reconsidered at predefined time points or events and adjusted, if needed, during the clinical development plan to enable greater inclusion with an aim of having the study population in late-stage or registration trials reflect as closely as possible the indicated population. Discussions with regulatory officials can also stress the importance of gathering safety data and including data on a broader array of patients in prescribing information. Eligibility criteria that affirmatively state inclusion of patients will help to overcome potential investigator or research staff bias against inclusion of patients such as those with prior and concurrent malignancies and comorbidities. Outreach to institutional review boards and scientific review committees to educate them on the importance of being inclusive will also help to overcome concerns that may arise from these oversight bodies.

In conclusion, to maximize the generalizability of clinical trial results, eligibility criteria should strive for inclusiveness to enroll participants who are representative of the intended users of the intervention under study in a timely manner. Rationale for excluding patients with characteristics should be clearly articulated and reflect expected toxicities associated with the therapy under investigation based on existing data. In cases where the toxicity profile of the drug is unknown, eligibility criteria should be adjusted over the course of the research process as greater understanding of the agent’s pharmacokinetics and tolerability are developed. We anticipate that current efforts to expand eligibility in several ongoing and planned clinical trials will help to demonstrate the feasibility of expanding eligibility and that future FDA guidance will assist sponsors in designing more representative trials. ASCO and Friends plan to work with the clinical trial community to encourage incorporation of these recommendations in new and existing trials and identify opportunities to track progress.

References

6. Fehrenbacher L, Ackerson L, Somkin C: Randomized clinical trial eligibility rates for chemo-therapy (CT) and antiangiogenic therapy (AAT) in a population-based cohort of newly diagnosed non-small cell lung cancer (NSCLC) patients. J Clin Oncol 27, 2009 (suppl 15s; abstr 6538)


Affiliations

Edward S. Kim, Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC; Suanna S. Bruinooge, Caroline Schenkel, and Richard L. Schilsky, ASCO, Alexandria, VA; Samantha Roberts, Marina Kozak, Jeff Allen, and Ellen Sigal, Friends of Cancer Research; Samantha Roberts, Genentech, Washington, DC; Gwynn Ison, Julia A. Beaver, Rajeshwari Sridhara, and Tatiana M. Prowell, US Food and Drug Administration, Silver Spring; Thomas S. Uldrick and Andrea M. Denicoff, National Cancer Institute, Bethesda, MD; Nancy U. Lin, Dana-Farber Cancer Institute, Boston; Paul J. Hesketh, Lahey Health Cancer Institute, Burlington, MA; Lia Gore, University of Colorado School of Medicine and Children’s Hospital Colorado, Aurora, CO; Stuart M. Lichtman, Memorial Sloan-Kettering Cancer Center, New York, NY; Nancy Roach, Fight Colorectal Cancer, Springfield, MO; Elizabeth Garrett-Mayer, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC; Eric Rubin, Merck Research Laboratories, Kenilworth, NJ; and Pratik Multani, Ignyta, San Diego, CA.

Support

Supported in part by Memorial Sloan-Kettering Cancer Center Support Grant No. P30 CA008748.
AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO’s conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/site/ifc.

Edward S. Kim
Honoraria: Celgene, Eli Lilly, AstraZeneca, Boehringer Ingelheim
Consulting or Advisory Role: Eli Lilly, Celgene, AstraZeneca, Boehringer Ingelheim

Suanna S. Bruinooge
No relationship to disclose

Samantha Roberts
Employment: Genentech

Gwynn Ison
No relationship to disclose

Nancy U. Lin
Research Funding: Genentech, GlaxoSmithKline, Array BioPharma, Novartis, Kadmon, Oncothyreon, Cascadian

Lia Gore
Employment: ARIAD (I)
Leadership: ARIAD (I)
Stock or Other Ownership: ARIAD (I), Amgen, Sanofi, Celgene, ARIAD, Clovis Oncology, Agios (I)
Honorable: Amgen
Consulting or Advisory Role: Celgene, MedImmune, Novartis, ProEd Communications, Genentech, Amgen, Medscape
Travel, Accommodations, Expenses: Amgen, Genentech

Thomas S. Uldrick
Research Funding: Celgene (Inst), Merck (Inst), Bayer (Inst), Genentech (Inst)
Patents, Royalties, Other Intellectual Property: As an employee of the US government, I have provisional patent application regarding methods for the treatment of Kaposi sarcoma and Kaposi sarcoma–associated herpesvirus–induced lymphoma using immunomodulatory compounds and uses of biomarkers (Inst)

Stuart M. Lichtman
Consulting or Advisory Role: Magellan Health

Nancy Roach
Travel, Accommodations, Expenses: Boehringer Ingelheim

Julia A. Beaver
No relationship to disclose

Rajeshwari Sridhara
No relationship to disclose

Paul J. Hesketh
No relationship to disclose

Andrea M. Denicoff
No relationship to disclose

Elizabeth Garrett-Mayer
Stock or Other Ownership: Abbott Laboratories, Abbvie
Consulting or Advisory Role: Tactical Therapeutics, Okava Pharmaceuticals

Eric Rubin
Employment: Merck

Pratik Multani
Employment: Ignyta
Leadership: Ignyta
Stock or Other Ownership: Ignyta

Tatiana M. Prowell
No relationship to disclose

Caroline Schenkel
No relationship to disclose

Marina Kozak
No relationship to disclose

Jeff Allen
No relationship to disclose

Ellen Sigal
Honoraria: AstraZeneca/MedImmune
Travel, Accommodations, Expenses: AstraZeneca/MedImmune, Alexandria Summit

Richard L. Schilsky
Research Funding: AstraZeneca (Inst), Bayer (Inst), Bristol-Myers Squibb (Inst), Genentech (Inst), Eli Lilly (Inst), Merck (Inst), Pfizer (Inst)
Acknowledgment

This article was developed as part of a collaboration between ASCO, Friends of Cancer Research, and the US Food and Drug Administration. The contents of this document were presented on May 12, 2016, and November 16, 2016, as part of collaborative workshops.